What is Immunovant Inc?
, a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 6.57B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 1027,430 shares $896k | 0 |
| 3-6months | 1018,904 shares $754k | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |